Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of RO4917523 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder With Inadequate Response to Ongoing Antidepressant Treatment.

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of RO4917523 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder With Inadequate Response to Ongoing Antidepressant Treatment.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Basimglurant (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms MARIGOLD
  • Sponsors Roche

Most Recent Events

  • 15 Jun 2016 Results published in the JAMA Psychiatry
  • 21 Oct 2014 Primary endpoint (Change in Montgomery Asberg Depression Rating Scale (MADRS)) has been met according to results presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
  • 21 Oct 2014 Results presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top